title: Ivermectin: a long-acting microfilaricidal agent.
abstract: Ivermectin is a macrocyclic lactone (fermentation) product and actinomycete (Streptomyces avermitilis) that possesses an unusually broad spectrum of potent activity against several species of nematodes, arachnids, and insects that parasitize domestic animals. From clinical trials in humans it has been found to be microfilaricidal, killing microfilariae of Onchocerca volvulus (the parasite causing onchocerciasis), and interrupting its transmission by the black fly vector. Dermal microfilariae density in patients are reduced to near zero levels for 6-12 months after a single oral dose of ivermectin 0.15-0.2 mg/kg. Its precise mechanism of action is unknown. It has a time to maximum concentration of 2.7-4.3 h, and an elimination half-life of 28 +/- 10 h. When compared with an oral solution the tablet dosage form has a relative bioavailability of approximately 60 percent. Not much is known about its metabolism in humans, and the unchanged drug is not detected in the urine. Controlled clinical trials have shown ivermectin to be associated with milder side effects than diethylcarbamazine, the current drug of choice for onchocerciasis therapy. It does not cause the severe Mazzoti-type (anaphylactoid) reactions that are associated with diethylcarbamazine use. Ivermectin is effective, safer, and more tolerable than diethylcarbamazine. It should, therefore, replace diethylcarbamazine as the drug of choice for onchocerciasis therapy.
authors.affiliation: University of Lagos, Nigeria.
authors.forename: E I
authors.initials: EI
authors.lastname: Ette
authors.forename: W O
authors.initials: WO
authors.lastname: Thomas
authors.forename: J I
authors.initials: JI
authors.lastname: Achumba
mesh_terms: D000818:Animals; D004347:Drug Interactions; D006801:Humans; D007559:Ivermectin / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D007559:Ivermectin